PF-06761281

Cat. No.: HY-120669

CAS No.: 1854061-19-0

Molecular Formula: $C_{13}H_{17}NO_6$

Molecular Weight: 283.28

Target: Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Storage: -20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : ≥ 50 mg/mL (176.50 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Concentration / Solvent / Mass	1 mg	5 mg	10 mg
1 mM	3.5301 mL	17.6504 mL	35.3008 mL
5 mM	0.7060 mL	3.5301 mL	7.0602 mL
10 mM	0.3530 mL	1.7650 mL	3.5301 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PF-06761281 (Compound 4a) is a potent, orally active, partial selective sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor with IC_{50} values of 0.51, 13.2 and 14.1 μM against HEK_{NaCT}, HEK_{NaDC1} and HEK_{NaDC3}, respectively[1].

IC_{50} & Target

IC_{50}: 0.51 μM (HEK_{NaCT}), 13.2 μM (HEK_{NaDC1}), 14.1 μM (HEK_{NaDC3})[1]

In Vitro

PF-06761281 (Compound 4a) inhibits citrate uptake with IC_{50} values of 0.12, 0.21 and 0.74 μM in rat, mouse and human Heps [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Huard K, et al. Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family. J Med Chem. 2016 Feb 11;59(3):1165-75.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA